Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMQBO3V)

Drug Name

M4344 Drug Info

Synonyms

VX-803; Butanehydrazide; Butyrohydrazide; Butyric acid hydrazide; 3538-65-6; butanehydrazide; Butanohydrazide; Butyrylhydrazine; Butanoic acid, hydrazide; n-Butyric acid hydrazide; butyric hydrazide; butanoic acid hydrazide; FCCCRBDJBTVFSJ-UHFFFAOYSA-N; butyryl hydrazine; Butanohydrazide #; EINECS 222-579-0; N-butanoyl-hydrazine; butryic acid hydrazide; ACMC-1AEKP; AC1L2SBF; AC1Q5PVE; SCHEMBL924945; Mr-I-33; ARONIS010643; SCHEMBL11029887; CTK3J2024; DTXSID70188869; MolPort-000-152-665; BDBM233138; NSC41957; NSC24021; KS-000041YT; ALBB-002745; ZINC1608800; NSC-240

Indication

Disease Entry	ICD 11	Status	REF
Solid tumour/cancer	2A00-2F9Z	Phase 1	[1]

Cross-matching ID

PubChem CID: 86720912
TTD Drug ID: DMQBO3V

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Clinical Trial Drug(s)

Investigative Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Serine/threonine-protein kinase ATR (FRP1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
AZD6738	DM0PFNC	Small-cell lung cancer	2C25.Y	Phase 2	[2]
RP-3500	DM9FNC8	Solid tumour/cancer	2A00-2F9Z	Phase 1/2	[3]
Camonsertib	DMOPPXY	Aggressive cancer	2A00-2F9Z	Phase 1/2	[4]
BAY1895344	DML781M	Lymphoma	2A80-2A86	Phase 1	[1]
VX-970	DMR9PCT	Solid tumour/cancer	2A00-2F9Z	Phase 1	[5]
M1774	DMP8QY2	Solid tumour/cancer	2A00-2F9Z	Phase 1	[6]
CGK733	DM8OAN9	Discovery agent	N.A.	Investigative	[7]
AZ20	DMNQ3HV	Discovery agent	N.A.	Investigative	[8]
VE-821	DM0UXNF	Solid tumour/cancer	2A00-2F9Z	Investigative	[5]
------------------------------------------------------------------------------------


⏷ Show the Full List of 9 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Serine/threonine-protein kinase ATR (FRP1)	TT8ZYBQ	ATR_HUMAN	Inhibitor	[1]

------------------------------------------------------------------------------------

References

1	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
2	National Cancer Institute Drug Dictionary (drug id 754022).
3	Clinical pipeline report, company report or official report of Repare Therapeutics.
4	Camonsertib in DNA damage response-deficient advanced solid tumors: phase 1 trial results. Nat Med. 2023 Jun;29(6):1400-1411.
5	ATR inhibitors VE-821 and VX-970 sensitize cancer cells to topoisomerase i inhibitors by disabling DNA replication initiation and fork elongation responses. Cancer Res. 2014 Dec 1;74(23):6968-79.
6	National Cancer Institute Drug Dictionary (drug name M1774).
7	Small molecule-based reversible reprogramming of cellular lifespan. Nat Chem Biol. 2006 Jul;2(7):369-74.
8	Discovery of 4-{4-[(3R)-3-Methylmorpholin-4-yl]-6-[1-(methylsulfonyl)cyclopropyl]pyrimidin-2-yl}-1H-indole (AZ20): a potent and selective inhibitor of ATR protein kinase with monotherapy in vivo antitumor activity. J Med Chem. 2013 Mar 14;56(5):2125-38.